In Monrovia, Liberia, the Liberian government’s recent decision to restrict the sale and use of abortion pills, known as Misoprostol, has ignited a fierce public backlash. The move, which has been condemned by human rights advocates and institutions, is seen as a threat to women’s health and a contradiction of national commitments to reduce maternal mortality.
The Ministry of Health has implemented a new policy that tightens controls on the sale and use of Misoprostol, also known as Cytotec. This synthetic prostaglandin is commonly used in obstetrics and gynecology for medical abortions, miscarriage management, and labor induction. Medical practitioners explain that the drug works by reducing stomach acid and inducing uterine contractions, which in turn causes bleeding and cramping to empty the uterus.
Announcing the new regulation on April 3, 2026, the government cited the widespread and unregulated sale and use of Misoprostol as the reason for the stricter controls. The Ministry of Health, in collaboration with the Liberia Medicines and Health Products Regulatory Authority (LMHRA), the Liberia Pharmacy Board (LPB), and the Liberia Medical and Dental Council (LMDC), emphasized that the drug must only be sold with a valid prescription from a licensed physician or authorized prescriber under Liberian law.
However, the policy has been met with criticism from the Liberia Sexual Reproductive Health and Rights Champions (SRHR-Champion Liberia), led by human rights advocate Titus B. Pakalah. Pakalah described the government’s action as a violation of Liberia’s health policy and a breach of its commitment to protect the health and well-being of women and girls under the National Action Plan aimed at reducing maternal deaths. “.
We express grave concern over the Ministry of Health’s directive tightening access to Misoprostol, particularly in light of the ongoing U. S. -Liberia health compact and the government’s own commitments under its 365-Day National Action Plan to address maternal mortality, “Pakalah stated.
He called for the full public disclosure of the U. S. -Liberia health compact implementation plan, including any policy changes affecting access to medicines and reproductive health services.
Pakalah argued that the new restrictions directly contradict national health priorities and warned that limiting access to Misoprostol would not stop its use but instead drive women toward unsafe practices. Human rights advocates also noted that the policy comes at a time when the government has pledged urgent action to reduce maternal mortality. According to Pakalah, restricting access to essential medicines undermines that goal and weakens public trust in the government’s reform agenda for inclusive development. “.
The impact of this restriction will be most severe for women and girls in rural communities, where access to licensed providers and regulated facilities is limited, “he. “For many, Misoprostol is the only realistic option. Increasing barriers and risks are pushing them into unsafe conditions with potentially fatal consequences.”.
